Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
For Research Purposes Only
Out of StockMolecular Profile
Molecular Profile
Type
Synthetic peptide (modified neurotrophic fragment)
Molecular formula
C₃₀H₅₄N₆O₅
Molecular weight
578.3 g/mol
Amino acids
6
Sequence
Ac-DGGLAG-NH₂
Modification
N-terminal acetylation; C-terminal amide; adamantane group covalently attached to the fifth residue, conferring lipophilicity and protease resistance.
Mechanism & Target Class
Mechanism & Target Class
P21 is a CNTF-derived peptide analog designed to target the IL-6 cytokine receptor family (CNTF/LIFR–gp130 complex). It mimics part of CNTF's receptor binding site (residues 148–151) while selectively modulating the leukemia inhibitory factor (LIF) branch of signaling via STAT3 interaction. This selectivity is associated with downstream engagement of BDNF–TrkB and CREB signaling cascades in preclinical models. The adamantane modification and N-terminal acetylation impart lipophilicity and protease resistance, properties examined in the context of blood–brain barrier permeability in animal studies. Pharmacokinetic characterization has examined oral stability and bioavailability in simulated physiological fluids.
Storage & Handling
Storage & Handling
Lyophilized
–20 °C
dry, protected from moisture and light.
Avoid repeated freeze-thaw cycles. Lyophilized form generally stable for months under recommended conditions.
References
References
Reviews
- 1
Kazim SF, Iqbal K. (2016). Mol Neurodegener
- 2
Iqbal K, Kazim SF, Bolognin S, et al. (2014). Neural Regen Res
Reviews
- 3
Baazaoui N, Iqbal K. (2022). Biomolecules
- 4
Ortiz Flores I, Treviño S, Díaz A. (2023). Neural Regen Res
- 5
Lozupone M, Dibello V, Sardone R, et al. (2023). Expert Opin Drug Discov
Primary research
- 6
Falangola MF, Voltin J, Cole M, et al. (2026). Magn Reson Imaging
- 7
Mottolese N, Loi M, Trazzi S, et al. (2024). J Neurodev Disord
- 8
Wei W, Liu Y, Dai C-L, et al. (2021). J Alzheimers Dis
- 9
Kazim SF, Blanchard J, Bianchi R, et al. (2017). Sci Rep
- 10
Baazaoui N, Iqbal K. (2017). Alzheimers Res Ther
- 11
Li B, Wanka L, Blanchard J, et al. (2010). FEBS Lett
- 12
Blanchard J, Chohan MO, Li B, et al. (2010). J Alzheimers Dis
- 13
Bolognin S, Blanchard J, Wang X, et al. (2012). Acta Neuropathol
- 14
Bolognin S, Buffelli M, Puoliväli J, et al. (2014). Neurobiol Aging
- 15
Kazim SF, Blanchard J, Dai C-L, et al. (2014). Neurobiol Dis
- 16
Chohan MO, Bragina O, Kazim SF, et al. (2015). Neurosurgery
- 17
Khatoon S, Chalbot S, Bolognin S, et al. (2015). J Alzheimers Dis
- 18
Baazaoui N, Iqbal K. (2017). J Alzheimers Dis
- 19
Baazaoui N, Iqbal K. (2018). J Alzheimers Dis
- 20
Liu Y, Wei W, Baazaoui N, et al. (2019). Front Aging Neurosci
- 21
Wei W, Wang Y, Liu Y, et al. (2020). Alzheimers Res Ther
Primary Database
Primary Database
Research Use Only. All products sold by Luvaminos are intended solely for in vitro research and laboratory use by qualified professionals. They are not approved by the FDA and are not intended for human or animal consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm you are a licensed researcher or institution and accept full responsibility for compliance with all applicable laws and regulations.
